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ABSTRACT
Dyslipidemia is a disease of abnormal lipid levels in the blood that contributes to the 
atherosclerotic process. This atherogenic process leads to the formation of plaque and also 
leads to thromboembolic events and other vascular accidents. It is known that high-density 
lipoprotein cholesterol serves as a protective effect on the vessel wall and causes the reduction 
in the progression of atherosclerosis. And multiple interventions are directed in maintaining a 
higher level of the aforementioned lipoprotein cholesterol. While the low-density lipoprotein 
stays controversial but lowering its levels through various therapeutic agents is the main goal in 
the management of dyslipidemia. A newer group of drugs, proprotein convertase subtilisin/kexin 
type 9 inhibitors lowers the levels of low-density lipoprotein through modulating proprotein 
convertase subtilisin/kexin type 9 gene involved in cholesterol metabolism and affects the levels 
of the lipoproteins by controlling the receptors. The inhibitors of this gene decrease proprotein 
convertase subtilisin/kexin type 9-induced low-density lipoprotein receptor degradation in the 
lysosomes of hepatocytes increasing its recfycling and expression on the cell surface, causing 
increased clearance of low-density lipoprotein from the circulation. These drugs Alicuromab, 
Evolocumab and along with other agents can be a novel approach in controlling dyslipidemic 
state. This review revisits the literature in understanding the pathophysiology of dyslipidemia 
along with its management by proprotein convertase subtilisin/kexin type 9 inhibitors, its 
mechanism of action, its pharmacokinetics, the results of the clinical trials and the limitations in 
its application.
INTRODUCTION
Atherosclerosis is a chronic inflammatory disease of the 
walls of large and medium-sized arteries. It is characterized 
by destruction of the normal arterial skeleton, involving 
collagen, elastin and smooth muscles, using enzymes and 
substituting this with disorderly laid collagen and elastin, 
along with cholesterol and foam cells [1]. Although a lot of 
information regarding atherosclerosis has been gained in the 
last five decades, it remains as one of the leading causes of 
mortality in both genders and the leading reason for poor 
quality of life [2]. This atherogenic cholesterol accumulation 
that damages the vascular anatomy is related to abnormal 
levels of lipid, often referred as dyslipidemia. Out of other 
causes of atherosclerosis, dyslipidemia stands prominently 
as a major contributor in the accumulation of fat in the lu-
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men, narrowing the diameter of the vessels, reducing the per 
unit time blood supply and a major source of thromboem-
bolic events. Dyslipidemia alone is related to stroke, tran-
sient ischemic attacks, ischemic heart disease, pulmonary 
and systemic embolism. Modulating the triggering elements 
of dyslipidemia or controlling this disease process can help 
control many other conditions, serve in comorbid process-
es and can help in a better quality of life. In past few de-
cades, with sedentary lifestyles, high caloric food intake and 
commercialized less organic food products, the tendency to 
develop dyslipidemia have increased many folds and the 
need for more effective regimens are needed. Statins have 
been used as a gold standard treatment for three decades 
now, although with knowing multiple aspects of the disease 
process, newer and more effectual treatment is needed. Pro-
protein convertase subtilisin/kexin type 9 (PCSK9) is a pro-
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tease and is expressed predominantly in the liver that plays a 
vital role in cholesterol metabolism by regulating the levels 
of low-density lipoprotein (LDL) receptors. PCSK9-inhibi-
tors inhibit PCSK9 induced low-density lipoprotein receptor 
degradation, increasing its recycling and expression on the 
cell surface, causing increased clearance of low-density lipo-
protein from the circulation and can therefore prove to be the 
wonder drug in management of hypercholesterolemia and 
help prevent atherosclerosis and development of congenital 
heart defect (CHD).
Atheroma Plaque Formation
When high-density lipoprotein (HDL) is not able to take up 
excess cholesterol from tissue turnover or maybe from di-
etary cholesterol that is accumulated as lipid layer along the 
blood vessels and serves in the formation of an atheroma 
plaque. It will be the role of inflammatory cells to digest the 
cholesterol not picked up by HDL and when inflammatory 
cells, particularly the macrophages, take up cholesterol, they 
cannot metabolize and become foam cells and start releas-
ing cytokines that cause an inflammatory environment of 
the vascular endothelium. When the intima gets inflamed, 
the repair would require fibrosis and collagen fibrous plaque 
would be formed on top of the necrotic core of lipids and 
cholesterol cleft – this fibrous plaque is called atheroma 
plaque [3]. Plaque formation is pathognomonic of athero-
sclerosis. Deposition of cholesterol in lesions in the arterial 
walls leads to the formation of plaques. This reduces the di-
ameter of the arterial lumen thereby decreasing the volume 
of blood per time that can pass through [2].
The blood analysis carried out during routine cholesterol 
level assessment is known as the lipid profile. This lipid pro-
file constitutes the following
• Low-density lipoprotein cholesterol (LDL-C)
• High-density lipoprotein cholesterol (HDL-C)
• Triglycerides (TGs) (blood fats)
Customarily, during evaluation of LDL-C and tri-
glycerides, values towards the lower end of the normal range 
are desired. This is due to the fact that these lipids are the 
main driving force behind the development and advancement 
of atherosclerosis. Conversely, a higher value of HDL-C, in 
most cases, is preferred as it offers a protective effect on the 
vessel walls and opposes the occurrence and progression 
of atherosclerosis [1, 4]. Studies carried on both men and 
women, suggests an inverse relationship between HDL-C 
and the risk of developing atherosclerosis, that is, a higher 
value of HDL-C means a lower risk for atherosclerosis while 
a lower value of HDL-C (1 milligram HDL-C per 1 decili-
ter of blood) indicates a greater risk for atherosclerosis [5]. 
Measurement of the cholesterol content of HDL-C was made 
possible due to advances in precipitation of apolipoprotein B 
(ApoB) containing lipoproteins. These measurements were 
done in a large number of subjects and this enabled grand 
scale epidemiological studies to determine the relationship 
between HDL-C and coronary heart disease. The reports that 
initially compelled the strong inverse association between 
HDL-C and coronary heart disease lead to Framingham 
Heart Study [6]. Data interpreted from this study formed the 
basis for the widely endorsed concept of HDL as the good 
cholesterol. This led to a conclusion that HDL may possess 
properties that are protective against coronary heart disease, 
in turn leading to the conclusion that raising the level of 
HDL-C through medical intervention would lessen the risk 
of coronary heart disease (the HDL hypothesis).
Controversy of HDL-C
Even though HDL-C has been shown to possess qualities 
that are protective against atherosclerosis, the association 
between HDL-C and atherosclerosis has not been clearly 
defined. Cynicism regarding the HDL hypothesis has arisen 
due to certain unsuccessful clinical trials and human genetic 
studies [7]. Despite the fact that there are questions regard-
ing the HDL hypothesis, the ability of HDL to predict cardio-
vascular events remains incontrovertible. Affirmation about 
HDL-C being a strong, consistent and independent predictor 
of cardiovascular incidences (myocardial infarction, isch-
emic stroke) has been displayed in multiple studies including 
various races and ethnicities all over the world [8,9]. Com-
pelling information has also been gathered regarding the role 
of HDL-C in predicting the risk of cardiovascular events 
for patients with known history of cardiac diseases, for the 
purpose of secondary prevention. The predictive property 
of HDL-C for cardiovascular events in patients undergoing 
treatment was accurate in a few clinical trials while in some 
others it was inaccurate [10, 11]. Also, the randomized con-
trolled trials and human genetic studies have provided much 
of the information that disputes the HDL hypothesis. Re-
search about Mendelian disorders has contributed much to 
this matter. The three Mendelian disorders causing primary 
extreme low HDL-C include mutations in apoA1, ABCA1, 
and LCAT [12]. Although HDL-C levels are lower than the 
5th percentile in all of these disorders, none of them are ex-
plicitly related to the development of premature coronary 
heart disease [12].
Furthermore, it has been proved that along with the part 
that LDL-C plays in raising the rate of cardiovascular events 
and, the supplementation of diet with statin therapy, exer-
cise, and stoppage of smoking are extremely efficacious in 
lowering the incidence and prevalence of hyperlipidemia. 
Although there is a presence of dependable genetic, biolog-
ical and epidemiological data as well as information from 
randomized trials, LDL-C remains a topic of controversy 
between national guidelines and clinical practice. Points of 
contention include measurement of LDL levels, benefits of 
population population-based screening, the net benefit to 
risk ratio for different drugs that decrease LDL, the useful-
ness of treatment targets and the safeness of vigorously low-
ering LDL [13].
Nonetheless, to this day, there have been various differ-
ent drugs that are used for the treatment of dyslipidemia that 
acts by lowering LDL-C and triglycerides.
Novel Treatment of Dyslipidemia
The safety and efficacy of statins have been proven in a 
large number of randomized clinical trials, therefore becom-
94 IMMINV 3(3):92-99
ing the drug of choice in treating atherogenic dyslipidemia. 
Nevertheless, even in the presence of optimum treatment 
with statins, there still remains a 60% to 80% risk of a car-
diovascular event [14]. In recent times, there has been a de-
velopment of a new class of lipid lipid-lowering drugs with 
some of them being made ready for use in clinical practice. 
The proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitor acts by increasing the production of low-density 
lipoprotein (LDL) receptors in hepatocytes. It achieves this 
by augmenting LDL receptor recycling [15]. The microso-
mal triglyceride transport protein (MTP) inhibitor and an-
tisense oligonucleotide against apolipoprotein B (Apo-B) 
act by decreasing the Apo-B containing lipoprotein. This is 
accomplished by obstructing the hepatic very low low-den-
sity lipoprotein synthesis pathway [16,17]. The apolipopro-
tein A1 (ApoA1) mimetics act by mimicking the effect of 
apolipoprotein A1. Their effects are similar to the protective 
effect of HDL-C and can even overturn the progress of ath-
erosclerosis [18]. However, some of the data gathered from 
clinical trials with Apo-A1 mimetics is contentious and fur-
ther testing is required for their acceptability in humans [13]. 
Encouraging results were shown by the PCSK9 inhibitors 
in recent studies, including a critical decrease in LDL-C in 
familial hypercholesterolemia patients from the long long-
term phase III trials.
History and Discovery of PCSK9
In the beginning, PCSK9 was classified as a new addition 
to the proprotein convertase family and was thought to be 
involved in some way in the differentiation of cortical neu-
rons and in the process of hepatic regeneration [19]. The 
PCSK9 (proprotein convertase subtilisin/kexin type 9 [MIM 
607786]) gene is responsible for encoding a cholesterol-reg-
ulated proprotein convertase. Selected missense mutations 
in PCSK9 were described in 2003, which gave rise to a new 
type of autosomal dominant hypercholesterolemia (MIM 
603776) [20]. This revelation brought to light a hitherto un-
known process that has a major impact on the circulating 
level of low-density lipoprotein cholesterol (LDL-C). The 
role of cholesterol in the regulation of PCSK9 was also not-
ed [20].
What is PCSK9 gene? Function and Physiology
PSCK9 became the 9th substance to be classified as a part 
of the subtilisin family of kexin-like proconvertases [21]. 
The signal sequence (amino acids 1-30) in PCSK9, in a 
similar fashion to the other members of the group, precedes 
the prodomain (amino acid 31-152) and the catalytic do-
main [19]. PCSK9 is classified as a 72-kd kD protease and 
is expressed predominantly in the liver. Structural properties 
of PCSK9 include three recognizable domains, a catalytic 
domain, an N-terminal prodomain and a carboxyl-termi-
nal domain whose function is as yet unknown. Similarities 
between the carboxyl-terminal domain and resistin, which 
is an inflammatory cytokine that is correlated with insulin 
resistance, were discovered on performing crystallograph-
ic studies [22]. PCSK9 plays a crucial part in cholesterol 
metabolism, which has led scientists in both academic and 
industrial circles to be highly optimistic regarding its role 
in the treatment of hypercholesterolemia. It›s Its mechanism 
of action includes regulation of LDL receptor levels [23]. 
These receptors are plasma membrane glycoproteins that 
cause the removal of cholesterol-rich LDL particles from the 
plasma [24,25]. Reduction in the level of LDL receptors oc-
curs due to gain-of-function mutations, leading to increased 
levels of LDL-C in plasma and increased risk of develop-
ment of cardiovascular disease. Conversely, loss-of-function 
mutations cause an increase in the number of LDL receptors, 
therefore decreasing the level of LDL-C and providing a 
protective effect against coronary heart disease [26,27].
Role of PCSK9 in Controlling Cholesterol
The process by which LDL receptor levels are decreased 
by PCSK9 has perplexed scientists for a long time, but 
progress in understanding its mechanism of action has been 
made due to studies conducted in recent years. PCSK9 ad-
heres to the LDL receptors which are present on the surface 
of cells. The elimination of LDL receptors involves inter-
nalization of this LDL receptor-PCSK9 complex. Within 
the cell, when this complex enters the endosome, the acidic 
environment causes an increase of about 150-fold in the af-
finity of PSCK9 for the LDL receptor [28,29]. The region 
which PCSK9 binds to on the LDL receptor is the epider-
mal growth factor (EGF)-like repeat A [28]. This region has 
been established to play a pivotal role in the recycling of the 
LDL receptor to the cell surface from the endosomes [30]. 
The binding site of PCSK9 on the LDL receptor is some 
distance away from its catalytic site, as disclosed by studies 
involving a crystal structure of PCSK9 bound to the EGF-
like repeat A [31]. Consequently, this binding of PCSK9 to 
the LDL receptor leads to a shift in the location of the LDL 
receptors from the cell surface to lysosomes [32]. In this 
manner, PCSK9 seems to divert the route of internalized 
LDL receptors, leading them to the lysosomes for destruc-
tion instead of the usual pathway of recycling to the cell 
surface [28,29,32]. (Figure 1)
PCSK9 Inhibitors: A new Regulator of Cholesterol 
Trafficking
Praluent (Alirocumab) injection is a new kind of drug 
that was approved for use by the U.S. Food and Drug Ad-
ministration on 24th July 2015. This drug became the first of 
its kind to be approved for the treatment of hyperlipidemia 
and belongs to a family of drugs known as proprotein con-
vertase subtilisin/kexin type 9 inhibitors [33].
Mechanism of Action
PCSK9 is classified as a serine protease and performs a 
critical part in the regulation of cholesterol metabolism in 
the liver. It achieves this by causing an increase in the de-
struction of LDL receptors. Surface expression of LDL 
receptors can be raised by inhibiting the process by using 
PCSK9 inhibitors which in turn decreases the degradation 
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Figure 1. Recycling of LDLR during the metabolism of LDL-C, in the absence (left) and in the presence (right) of PCSK9. Right side 
shows LDL-C particle attachment to the LDLR and subsequent endocytosis via clathrin-coated vesicle. LDL-C is then degraded in 
the endosome while LDLR is recycled back on to the surface of hepatocyte. Left side shows binding of PCSK9 to the LDL-C-LDLR 
complex with subsequent internalization, however the presence of PCSK9 on LDLR directs this vesicle to the lysosomes where the 
LDLRs are degraded in an acidic environment. (LDL-C, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; 
PCSK9, proprotein convertase subtilisin/kexin type 9.)
Figure 2. Effect of PCSK9 inhibitors on LDL-C metabolism. Under physiologic conditions, LDLRs and PCSK9 are synthesized in hepatocytes 
and are secreted into the circulation. Here LDLRs binds LDL-C and is also attached by PCSK9. This complex is endocytosed and directed to 
lysosome by PCSK9 for destruction. Fewer LDLRs are recycled to the surface of hepatocytes to remove LDL-C. PCSK9 inhibitors, however, 
prevents this destruction of LDLRs in lysosome and more LDLRs are recycled back to remove LDL-C from the circulation. (LDL-C, low-
density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9)
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of LDL receptors (LDLRs). This leads to an increase in the 
recycling of LDLRs which subsequently causes a reduction 
in the levels of LDL-C (Figure 2). Various methods have 
been suggested for the inhibition of PCSK9 so far. Some of 
these include small interfering RNA, monoclonal antibodies, 
mimetic peptides and antisense oligonucleotides. Out of all 
of these, the most promising data on humans has indubitably 
been displayed by the fully humanized monoclonal antibody 
against PCSK9 [34].
Kinetics of PCSK9 Inhibitors
Alirocumab
Maximum serum concentration is achieved in 3-7 days and the 
serum concentration-time profiles for different injection sites, 
including the abdomen, upper arm and thigh are almost alike. 
On average, about 3-4 doses are required to achieve steady 
steady-state concentration. When administered intravenously, 
the volume of distribution is 0.04 to 0.05 L/Kg. When given 
at a dose of 75mg to 150mg every fortnight, the median half-
life (t1/2) was revealed to be between 17 to 20 days. Removal 
of Alirocumab occurs in two phases, based on its concentra-
tion in plasma. When the concentration in plasma is low, the 
main route by which Alirocumab is eliminated is by saturation 
of the targets (PCSK9) bound to the antibodies. On the other 
hand, when plasma concentration is high, the proteolytic path-
ways are the predominant mode of elimination [35].
Evolocumab
Evolocumab exhibits non-linear pharmacokinetic properties 
in absorption when the dosage is less than 140mg. Con-
versely, when the dosage is between 140mg to 420mg, it is 
noted that the pharmacokinetics become linear. Following 
administration of one dose, 3-4 days are required to achieve 
maximum concentration. Administration of a solitary dose 
of 420mg results in approximately 3.3 L ± 0.5 L of the vol-
ume of distribution. Dosing for nearly 12 weeks is needed 
to obtain a steady steady-state in serum. Evolocumab has a 
half half-life (t1/2) somewhere between 11 days to 17 days. 
A Dosage dosage of 140mg once a fortnight and dosage of 
420mg once monthly produced nearly identical results in 
maximal lowering LDL cholesterol levels and took about 
14 days to take effect. Mild and moderate dysfunction of liv-
er or kidneys does not produce any variation in the pharma-
cokinetics of Evolocumab according to data collected during 
clinical studies. On the other hand, no data is available re-
garding the effect on pharmacokinetics in individuals with 
severe hepatic and renal impairment [36].
Clinical Trials
In contrast to treatment with statins alone, the addition of 
monoclonal antibodies that inhibit PSCK9 along with sta-
tin therapy brings a 50%-60% further lowering of LDL-C, 
as shown by phase I, II, and III trials. Data collected from 
short-term trials show that PCSK9 inhibitors had a very low 
occurrence of harmful effects and were tolerated reasonably 
well. Data is being gathered by progressive phase III trials 
which will tell whether the drug is safe to use over a long pe-
riod of time and its effectiveness in averting cardiovascular 
disease [37].
In comparison to a placebo, Alirocumab, and Evolocum-
ab, which are both administered by injection, cause a mas-
sive decrease in the level of LDL-C (39 to 62% decrease 
for Alirocumab and 47 to 56% for Evolocumab). Level of 
LDL-C decreased to less than 25mg per deciliter on two suc-
cessive readings in about 37% of subjects being treated with 
Evolocumab and about 24% of subjects being treated with 
Alirocumab during programs for developing the drugs [38]. 
During studies conducted on animals, it was found that inhi-
bition of PCSK9 in zebrafish embryos leads to disorganized 
neuronal growth and can be fatal [39]. However, lackof 
PCSK9 in mice does not cause any neurological problems 
and their growth occurs normally [40]. In humans, individ-
uals who are heterozygous for loss-of-function mutations in 
PCSK9 appear to have no health issues and have similar life 
spans as individuals with no mutations [26,41]. A study was 
conducted on PCSK9 involving 18 subjects, 10 females and 
8 males, and was divided into two time periods along with 
being placebo-controlled. The subjects were given two doses 
of placebo at a gap of two weeks after which they were ad-
ministered 5 doses of 150mg of Alirocumab at a gap of two 
weeks each. Effect of Alirocumab was to decrease LDL-C, 
separated by ultracentrifugation, by 55.1%. LDL-ApoB was 
decreased by 56.3% and reduction in plasma Lp lipoprotein 
(a) was 18.7%. An 80.4% rise in LDL-ApoB FCR (Frac-
tional catabolic rate) along with a 23.9% decrease in LDL-
ApoB PR (Production rate) appears to be the main cause of 
the reduction of LDL-ApoB. The LDL-ApoB is related to a 
46.1% rise in IDL-ApoB FCR linked with a 27.2% reduction 
in the formation of LDL from IDL. There was no variation in 
apo(a) PR ApoA1 PR while the FCR of apo(a) ApoA1 was 
prone to increase. No effect of Alirocumab was observed on 
FCRs or PRs of VLDL-ApoB and VLDL-TG (Triglyceride) 
as well as on plasma TG after meals or ApoB48 levels [42].
A trial conducted to investigate the effectiveness of 
PCSK9 inhibitors, known as the Therapy for Easing Lipid 
Levels (MENDEL) trial, included 406 subjects with hyper-
cholesterolemia and intolerance to statin therapy. The sub-
jects were randomly divided into groups and each group was 
allocated a treatment regimen. These included a fortnightly 
dose of 70mg, 105mg and 140 mg of Evolocumab; a month-
ly dose of 280mg, 350mg, and 420mg of Evolocumab; fort-
nightly or monthly dose of placebo or a single daily dose 
of Ezetimibe. LDL-C levels were decreased in all groups 
with Evolocumab and the maximum effect was shown by 
the dosage of 140mg every fortnight (~51 %) without any 
harmful side effects being observed [43]. Massive improve-
ment in LDL-C level by Alirocumab and Evolocumab were 
reported in one review. The results were more powerful for 
Alirocumab, as compared to Evolocumab, in subjects at 
high risk of a cardiovascular event who had poor LDL-C 
levels. Conversely, in subjects with heterogeneous familial 
hypercholesterolemia and subjects with varied risk of a car-
diovascular event with deranged LDL-C values, Evolocum-
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ab showed a greater result. Data collected from a previous 
analysis on adjudicated cardiovascular outcomes showed no 
significant advantage for Alirocumab and was inconclusive 
for Evolocumab. But for longer duration use, vital answers 
are still required regarding the effects of both Evolocumab 
and Alirocumab on health and fitness [44]. An additional 
clinical trial was conducted with 968 subjects who all had 
a history of cardiovascular disease. They were also divided 
into two groups at random and one was given the PCSK9 
inhibitor Evolocumab while the other group was assigned a 
placebo. The drugs were taken once a month for 19 months 
and intravascular ultrasounds were done sequentially to as-
certain the volume of coronary atheroma. In the Evolocum-
ab group, the LDL-C levels were noted to be lower (36.6 
vs 93.0 mg/dL) and the number of subjects showing plaque 
reversal was observed to be higher (64.3% vs 47.3%). The 
Evolocumab group also showed a decrease in the percent 
atheroma volume (−0.95%). No such effect was noted for the 
placebo group [45].
The debate about the efficacy and possible negative con-
sequences of these unfamiliar drugs is ongoing and has in-
volved a multitude of experts.
Clinical uses of PCSK9 Inhibitors
One of the chief advantages of PCSK9 inhibitors is its usage 
in therapy for familial hypercholesterolemia in people over-
ly sensitive to statins and also in people whose low-density 
lipoprotein-cholesterol LDL-C levels remain high even after 
they have been put on the maximum dose of statins that can 
be safely prescribed. Interestingly, combination therapy of 
low dose statins with PCSK9 inhibitors is more efficacious 
for decreasing LDL-C levels and preventing adverse effects 
of statins. This is due to the fact that combination of PCSK9 
inhibitors with both low dose and high dose statins have 
shown effects nearly identical to each other [46].
Potential Barriers
Large-scale use of PCSK9 inhibitors may be prevented by 
the presence of various probable hurdles. First of all, the ef-
ficacy of statins in treating hypercholesterolemia has been 
confirmed by the results of several long long-term studies, 
this makes statins a better option over the PCSK9 inhibitors, 
which is still to evaluated in terms of outcomes, efficacy and 
side-effects. [47,48]. This lack of extensive post-market tri-
als and primitive phases of surveillance makes it a potential 
barrier in physician’s first choice over statins. Additionally, 
a further hurdle faced by the PCSK9 inhibitors may be their 
retail price. According to The Institute for Clinical and Eco-
nomic Review (ICER), the amount required for treatment 
for 5 years to prevent a single major cardiovascular inci-
dent (NNT5) happens to be 28. But the cost-effectiveness 
ratio calculated by the manufacturer’s suggested retail price 
is much higher than the established threshold of $100000/
quality-affected life-years.  A drop of 60% to 65% in the 
 presently suggested price would be needed to attain cost-ef-
fectiveness at this threshold [49].
Adverse effects and Contraindications of Alirocumab 
and Evolocumab
Data collected from more than 7000 patients who were being 
given PCSK9 inhibitors has been observed and the side ef-
fects recorded tillnow state the findings as mentioned below. 
Treatment with Alirocumab is not advisable in people who 
are sensitive to it and may in the past have displayed severe 
hypersensitivity reactions like hypersensitivity vasculitis or 
needed a hospital stay due to a severe allergic reaction after 
its consumption. The most frequently reported side effects of 
Alirocumab are: nasopharyngitis, injection site reactions (er-
ythema, itchiness, swelling, pain or tenderness), influenza, 
urinary tract infection, diarrhea, bronchitis, myalgia, mus-
cle spasms, sinusitis, cough, contusion and musculoskeletal 
pain. The most frequent reasons for stoppage of drug use 
include allergic reactions and elevated liver enzymes [46].
Reasons for the avoidance of Evolocumab are mostly the 
same as those for Alirocumab. In comparison to a placebo, 
the occurrence of negative effects for a single dose of 140mg 
Evolocumab once a fortnight was 43.6% (Evolocumab) vs 
41% (placebo). The most frequent side effects reported were 
nasopharyngitis, upper respiratory tract infection, back pain 
and nausea. The most frequent reasons for halting drug use 
were dizziness, myalgia, and nausea. Some of the more se-
vere side effects include cardiovascular disorders, seen in 
2.4% of the patients, like palpitations, angina pectoris, and 
ventricular extrasystoles [46]. Furthermore, information col-
lected from various clinical trials which assessed Evolocum-
ab and Alirocumab has displayed that individuals on PCSK9 
inhibitor therapy have exhibited a greater amount of side ef-
fects involving cognitive ability [36, 50].
CONCLUSION
An essential aspect of assessing pharmaceutical drugs be-
longing to a new class is to demonstrate proof of their intend-
ed effect on the subject, which in this case is a decreased risk 
of cardiovascular incidents. Even though with Alirocumab 
and Evolocumab the decrease in LDL-C is considerable, con-
clusive proof that the rate of occurrence of cardiovascular in-
cidents has lowered is indispensable. A few clinical trials are 
specifically being conducted to gather data that can be used 
to illuminate the clinical advantages of these drugs as well as 
potential adverse effects. The possible advantages from the 
remarkable decrease in LDL-C levels achieved by these med-
ications should be cautiously evaluated in contrast to their 
long long-term safety profile which is as yet inconclusive.
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